Harnessing tetrahedral framework nucleic acids for enhanced delivery of microRNA-149-3p: A new frontier in oral squamous cell carcinoma therapy

Abstract

Oral squamous cell carcinoma (OSCC), a type of malignant tumour that primarily occurs in the oral mucosa, has drawn considerable attention owing to its aggressive growth and potentially high metastatic rate. Surgical resection is the primary treatment method for OSCC and is typically combined with radiation therapy and chemotherapy. microRNA-149-3p (miR-149) is a negative regulator of the Pi3k/Akt pathway and can effectively inhibit the proliferation of tumour cells. However, the application of miR-149 is limited owing to its relatively low efficiency of cellular uptake and poor stability when used alone. To overcome these challenges, this study adopted a novel nucleic acid nanostructured material, tetrahedral framework nucleic acids (tFNAs). The use of tFNAs as carriers to assemble the T-miR-149 complex reduced the expression of Pi3k and Akt involved in tumorigenesis and alterations in proteins related to cell apoptosis. The results indicated that the bionic drug delivery system has an effective tumour suppressive effect on OSCC in mice, revealing its potential clinical value in the treatment of OSCC.

References

[1] BugshanA, FarooqI. Oral squamous cell carcinoma: metastasis, potentially associated malignant disorders, etiology and recent advancements in diagnosis. F1000Res. 2020;9:229.

[2] CheJ, ZhaoT, LiuW, et al. Neochlorogenic acid enhances the antitumor effects of pingyangmycin via regulating TOP2A. Mol Med Rep. 2021;23(2):158.

[3] PanS, SuY, SunB, HaoR, GaoX, HanB. Knockout of CD147 inhibits the proliferation, invasion, and drug resistance of human oral cancer CAL27 cells in vitro and in vivo. Int J Biol Macromol. 2021;181:378-389.

[4] ZhanY, ZhangY, MaoC, et al. Improved tumor infiltration and immunomodulation for tumor therapy: a pathway based on tetrahedral framework nucleic acids coupled bacterial nanocells. Nano Lett. 2023;23(1):353-362.

[5] ZhiY, ZhouH, MubalakeA, et al. Regulation and functions of microRNA-149 in human cancers. Cell Prolif. 2018;51(5):e12465.

[6] LiXQ, JiaYL, ZhangYW, Chen HY, XuJJ. Intracellular activated logic nanomachines based on framework nucleic acids for low background detection of microRNAs in living cells. Chem Sci. 2023;14(28):7699-7708.

[7] da SilvaKR, Veronez LC, CorreaCAP, et al. MicroRNA-149-3p expression correlates with outcomes of adrenocortical tumor patients and affects proliferation and cell cycle progression of H295A adrenocortical cancer cell line. Hum Cell. 2022;35(6):1952-1960.

[8] ShenQ, XiongP, YangD, Chen L. Downregulated microRNA-149-3p triggers malignant development and predicts worse prognosis in oral squamous cell carcinoma. Arch Oral Biol. 2022;134:105336.

[9] MenonA, Abd-Aziz N, KhalidK, PohCL, NaiduR. miRNA: a promising therapeutic target in cancer. Int J Mol Sci. 2022;23(19):11502.

[10] LiY, CaiZ, MaW, BaiL, LuoE, LinY. A DNA tetrahedron-based ferroptosis-suppressing nanoparticle: superior delivery of curcumin and alleviation of diabetic osteoporosis. Bone Res. 2024;12(1):14.

[11] HanahanD, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-674.

[12] ShenQ, ZhuH, LeiQ, ChenL, YangD, Sui W. MicroRNA-149-3p inhibits cell proliferation by targeting AKT2 in oral squamous cell carcinoma. Mol Med Rep. 2021;23(3):172.

[13] LiuY, LiS, LinS, et al. A tetrahedral framework nucleic acid based multifunctional nanocapsule for tumor prophylactic mRNA vaccination. Chinese Chem Lett. 2023;34(7):107987.

[14] KrolJ, Loedige I, FilipowiczW. The widespread regulation of microRNA biogenesis, function and decay. Nat Rev Genet. 2010;11(9):597-610.

[15] GaoY, ChenX, TianT, et al. A lysosome-activated tetrahedral nanobox for encapsulated siRNA delivery. Adv Mater. 2022;34(46):e2201731.

[16] LiJ, YaoY, WangY, et al. Modulation of the crosstalk between Schwann cells and macrophages for nerve regeneration: a therapeutic strategy based on a multifunctional tetrahedral framework nucleic acids system. Adv Mater. 2022;34(46):e2202513.

[17] WangQ, ChengJ, LiuF, et al. Modulation of cerebrospinal fluid dysregulation via a SPAK and OSR1 targeted framework nucleic acid in hydrocephalus. Adv Sci. 2024;e2306622. doi:10.1002/advs.202306622

[18] LiS, LiuY, ZhangT, et al. A tetrahedral framework DNA-based bioswitchable miRNA inhibitor delivery system: application to skin anti-aging. Adv Mater. 2022;34(46):e2204287.

[19] MaW, YangY, ZhuJ, et al. Biomimetic nanoerythrosome-coated aptamer-DNA tetrahedron/maytansine conjugates: pH-responsive and targeted cytotoxicity for HER2-positive breast cancer. Adv Mater. 2022;34(46):e2109609.

[20] QinX, XiaoL, LiN, et al. Tetrahedral framework nucleic acids-based delivery of microRNA-155 inhibits choroidal neovascularization by regulating the polarization of macrophages. Bioact Mater. 2022;14:134-144.

[21] TianT, LiY, LinY. Prospects and challenges of dynamic DNA nanostructures in biomedical applications. Bone Res. 2022;10(1):40.

[22] HeY, LanY, LiuY, et al. Pingyangmycin and bleomycin share the same cytotoxicity pathway. Molecules. 2016;21(7):862.

[23] TianT, ZhangT, ShiS, GaoY, CaiX, LinY. A dynamic DNA tetrahedron framework for active targeting. Nat Protoc. 2023;18(4):1028-1055.

[24] JiangY, WangX, HuD. Furanodienone induces G0/G1 arrest and causes apoptosis via the ROS/MAPKs-mediated caspase-dependent pathway in human colorectal cancer cells: a study in vitro and in vivo. Cell Death Dis. 2017;8(5):e2815.

[25] MengLY, LiuHR, ShenY, Yu YQ, TaoX. Cochinchina momordica seed extract induces G2/M arrest and apoptosis in human breast cancer MDA-MB-231 cells by modulating the PI3K/Akt pathway. Asian Pac J Cancer Prev. 2011;12(12):3483-3488.

[26] ZhangT, TianT, ZhouR, et al. Design, fabrication and applications of tetrahedral DNA nanostructure-based multifunctional complexes in drug delivery and biomedical treatment. Nat Protoc. 2020;15(8):2728-2757.

[27] HeF, ZhouX, HuangG, Jiang Q, WanL, QiuJ. Establishment and identification of patient-derived xenograft model for oral squamous cell carcinoma. J Oncol. 2022;2022:3135470.

[28] ChenY, ChenX, ZhangB, et al. DNA framework signal amplification platform-based high-throughput immune-cell phenotyping system for rapid systemic immune monitoring. Signal Transduct Target Ther. 2024;9(1):28.

[29] González-GonzálezR, Ortiz-SarabiaG, Molina-Frechero N, et al. Epithelial-mesenchymal transition associated with head and neck squamous cell carcinomas: a review. Cancer. 2021;13(12):3027.

[30] SekarD, Selvakumar SC, AuxziliaPK. Therapeutic nature of microRNAs in oral squamous cell carcinoma (OSCC). Oral Oncol. 2022;134:106106.

[31] SongX, LiL, ShiL, et al. C1QTNF6 promotes oral squamous cell carcinoma by enhancing proliferation and inhibiting apoptosis. Cancer Cell Int. 2021;21(1):666.

[32] ZhangY, MaS, LiuX, et al. Supramolecular assembled programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy. Adv Mater. 2021;33(7):e2007293.

[33] WenZ, ZhangY, WangX, et al. THBS1-mediated degradation of collagen via the PI3K/AKT pathway facilitates the metastasis and poor prognosis of OSCC. Int J Mol Sci. 2023;24(17):13312.

[34] YangC, ZhangJ, DingM, et al. Ki67 targeted strategies for cancer therapy. Clin Transl Oncol. 2018;20(5):570-575.

[35] GuoR, MaL, BaiX, MiaoL, LiZ, YangJ. A scoring method for immunohistochemical staining on Ki67. Appl Immunohistochem Mol Morphol. 2021;29(3):e20-e28.

[36] AlamM, Kashyap T, MishraP, PandaAK, NaginiS, MishraR. Role and regulation of proapoptotic Bax in oral squamous cell carcinoma and drug resistance. Head Neck. 2019;41(1):185-197.

[37] GongX, TangH, YangK. PER1 suppresses glycolysis and cell proliferation in oral squamous cell carcinoma via the PER1/RACK1/PI3K signaling complex. Cell Death Dis. 2021;12(3):276.

[38] QuXH, ShiYL, MaY, et al. LncRNA DANCR regulates the growth and metastasis of oral squamous cell carcinoma cells via altering miR-216a-5p expression. Hum Cell. 2020;33(4):1281-1293.

[39] BrierlyG, Celentano A, BreikO, et al. Tumour necrosis factor alpha (TNF-α) and oral squamous cell carcinoma. Cancer. 2023;15(6):1841.

[40] LaiKC, LiuCJ, LinTJ, et al. Blocking TNF-α inhibits angiogenesis and growth of IFIT2-depleted metastatic oral squamous cell carcinoma cells. Cancer Lett. 2016;370(2):207-215.

[41] WangS, WangX, SunJ, et al. Down-regulation of DNA key protein-FEN1 inhibits OSCC growth by affecting immunosuppressive phenotypes via IFN-γ/JAK/STAT-1. Int J Oral Sci. 2023;15(1):17.

[42] LiY, LiJ, ChangY, Lin Y, SuiL. Tetrahedral framework nucleic acids promote the proliferation and differentiation potential of diabetic bone marrow mesenchymal stem cell. Chinese Chem Lett. 2023;109414.

[43] AngMJY, ChanSY, GohY-Y, Luo Z, LauJW, LiuX. Emerging strategies in developing multifunctional nanomaterials for cancer nanotheranostics. Adv Drug Deliv Rev. 2021;178:113907.

[44] FilipowiczW, Bhattacharyya SN, SonenbergN. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet. 2008;9(2):102-114.

[45] YangCY, LiuCR, ChangIY, et al. Cotargeting CHK1 and PI3K synergistically suppresses tumor growth of oral cavity squamous cell carcinoma in patient-derived xenografts. Cancer. 2020;12(7):1726.

[46] TangB, MaW, LinY. Emerging applications of anti-angiogenic nanomaterials in oncotherapy. J Control Release. 2023;364:61-78.

[47] LiJ, WangQ, XiaG, et al. Recent advances in targeted drug delivery strategy for enhancing oncotherapy. Pharmaceutics. 2023;15(9):2233.

RIGHTS & PERMISSIONS

2024 The Authors. Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.